ArticleScientific reports2025
OLR1 is closely related to poor prognosis and immune cell infiltration in gastric cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- OLR1 drives gastric cancer progression through NF-κB activation and immunosuppressive macrophage polarization.Medical oncology (Northwood, London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Oxidized low-density lipoprotein receptor 1 (OLR1) in gastric cancer (GC) progression and immune cell infiltration remains unclear. This study aimed to investigate the impact of OLR1 on GC progression and to elucidate its association with immune cell infiltration in GC. OLR1 expression profiles in GC and paired normal tissues were analyzed using datasets from the TCGA, GTEx, and GEO databases, with validation conducted through quantitative real-time PCR (qPCR) and immunohistochemistry (IHC). Differentially expressed genes (DEGs) associated with OLR1 were identified through gene set enrichment analysis (GSEA) and functional enrichment analysis. We evaluated the role of OLR1 in GC immune cell infiltration. In addition, Cox regression and Kaplan-Meier analyses were conducted on OLR1 for its prognostic significance and correlation with clinical variables. We evaluated the role of OLR1 in gastric cancer cell invasion and migration via Transwell and wound-healing assays following OLR1 knockdown and overexpression. Finally, survival probabilities in GC patients were predicted by nomogram construction. OLR1 expression in GC tissues significantly increased relative to that in matched normal samples (P < 0.001), as confirmed by qPCR and IHC (both P < 0.05). There were 268 DEGs associated with Staphylococcus aureus infection, protein digestion and absorption signaling, and the estrogen signaling pathway. OLR1 expression was positively related to macrophage infiltration (r = 0.742, P < 0.001, as validated by IHC). Additionally, OLR1 expression was strongly related to histological grade (P < 0.001), histological type (P < 0.05), T stage (P < 0.01), pathological stage (P < 0.05), and unfavorable overall survival (OS, P < 0.05). In vitro findings indicate that OLR1 enhances the invasive and migratory abilities of gastric cancer cells. Our established nomogram effectively predicted the 1-, 3-, and 5-year OS probabilities in patients with GC (C-index [95% CI] = 0.649 [0.624-0.675]). OLR1 is strongly associated with a dismal prognostic outcome and immune cell infiltration in patients with GC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.